Dexcom

New South Wales, AUS
Total Offices: 5
7,214 Total Employees
Year Founded: 1999
View Website

Jobs at Similar Companies

Similar Companies Hiring

Camber Logo

Camber

Social Impact • Healthtech • Fintech
New York, NY
53 Employees
Sailor Health Logo

Sailor Health

Telehealth • Social Impact • Healthtech
New York City, NY
20 Employees
Granted Logo

Granted

Mobile • Insurance • Healthtech • Financial Services • Artificial Intelligence
New York, New York
23 Employees

Dexcom Company Stability & Growth

Updated on February 03, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for Dexcom?

Strengths in revenue growth, product cadence, and international expansion are accompanied by competitive and operational challenges, including pricing pressure risk and manufacturing/quality scrutiny. Together, these dynamics suggest continued category expansion with execution on quality, pricing, and rollout pacing as key to sustaining momentum.
Positive Themes About Dexcom
  • Strong Revenue Growth: Revenue guidance for 2026 indicates 11–13% growth on top of robust 2025 expansion, supported by sensor volume increases, Stelo rollout, the G7 15‑Day system, and broader international penetration. Quarterly updates also showed double‑digit growth across U.S. and international segments.
  • Market Expansion: International CGM expansion is emphasized under the new CEO, with coverage broadening to type 2 diabetics and pre‑diabetes and opportunities in gestational diabetes. Active customers grew over 20% by year‑end 2025, and adoption outside the U.S. accelerated with G7 rollout and reimbursement wins.
  • Product Line Growth: The launch of Stelo for non‑insulin users and the extended‑wear G7 15‑Day broaden use cases and support margin and growth into 2026. Pipeline and ecosystem enhancements (including integrations and app features) further reinforce product momentum.
Considerations About Dexcom
  • Weak Market Position & Pricing Challenges: Intense competition with Abbott’s Libre franchise and potential U.S. reimbursement changes (such as possible competitive bidding) create pricing and share headwinds. Commentary notes Abbott’s larger worldwide installed base and aggressive pricing in certain markets.
  • Operational Inefficiency: Execution risks surfaced around manufacturing and quality, including an FDA warning letter and inventory/write‑off items that pressured margins at times. Facility transitions and restructuring add near‑term operational complexity despite longer‑term efficiency goals.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
AI Report
AI Report
The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.
View All 1 Jobs at Dexcom
Is This Your Company? Claim Profile